Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~At V1 (screening), patient must be/have:~1. Written informed consent signed by patient.~2. Aged 16 years or more (patients under 18 years of age require parental/legal representative consent). In North America as well as in other participating countries, when appropriate and/or required by state or local law, minor patients must give written informed assent prior to participation in the study.~3. A documented diagnosis of epilepsy since at least 12 months prior to screening.~4. At least 4 partial-onset seizures (including subtypes of simple partial, complex partial and partial seizures evolving to secondarily generalised) on the 4 weeks prior to screening.~5. Currently treated with 1 or 2 AEDs (any except OXC), in a stable dose regimen during at least 1 month prior to screening. Patients using vigabatrin should have been on this medication for at least 1 year with no deficit in visual field identified (a confirmatory test should be available within 1 month before study entry). The device for VNS should be implanted at least 6 months before screening; parameters need to be stable for at least 1 month prior to screening (VNS will not be counted as concomitant AED).~6. Excepting epilepsy, patient is judged to be in general good health based on medical history, physical examination findings, and clinical laboratory test results.~7. Post-menopausal or otherwise incapable of becoming pregnant by reason of surgery or tubal ligation. In case of women of childbearing potential (WOCBP), patient must present a serum beta-human chorionic gonadotropin (B-hCG) test consistent with a non gravid state and agree to remain abstinent or use reliable contraception (hormonal contraception should be combined with a barrier method) beginning at screening and continuing at least to the PSV.~   At V2 (randomisation), patient must have:~8. At least 8 partial-onset seizures during baseline with at least 3 partial-onset seizures in each 4-week section of the 8-week baseline period prior to randomisation (documented in a diary) and no seizure-free interval exceeding 28 consecutive days.~9. In case of WOCBP, patient must present a urine B-hCG test consistent with a non gravid state.~10. Diaries satisfactorily completed by the patient or his/her caregiver.~11. Satisfactorily complied with the study requirements during the baseline period (including no changes in concomitant AED therapy should have occurred in the baseline period).~Exclusion Criteria~At V1 (screening), patients must not be/have:~1. Only simple partial seizures with no motor symptomatology (classified as A2 4 according to the International Classification of Epileptic Seizures).~2. Primarily generalised seizures.~3. Known progressive neurological disorders (progressive brain disease; epilepsy secondary to progressive cerebral lesion).~4. Occurrence of seizures too close to count accurately.~5. History of status epilepticus or cluster seizures (i.e., 3 or more seizures within 30 minutes) within the 3 months prior to screening.~6. Seizures of non-epileptic origin.~7. Seizures of psychogenic origin within the last 2 years.~8. Major psychiatric disorders.~9. Documented diagnosis of schizophrenia with accompanying documented history of at least 1 acute psychosis episode within the last 2 years) or history of suicide attempt.~10. Currently treated with OXC.~11. Using benzodiazepines on more than an occasional basis (defined as more than 2 times per week), except when used chronically as AED.~12. Known exposure to Eslicarbazepine acetate from previous study.~    o Previous use of Eslicarbazepine acetate or participation in a clinical study with Eslicarbazepine acetate (patients not exposed to Eslicarbazepine acetate \[e.g., screen failed\] are allowed).~13. Known hypersensitivity to carboxamide derivatives.~14. History of abuse of alcohol, drugs or medications within the last 2 years.~15. Uncontrolled cardiac, renal, hepatic, endocrine, gastrointestinal, metabolic, haematological or oncology disorder.~16. Second or third-degree atrioventricular blockade not corrected with a pacemaker.~17. Relevant clinical laboratory abnormalities (e.g., sodium \<130 mmol/L, alanine or aspartate transaminases \>2.0 times the upper limit of the normal, white blood cell \[WBC\] count \<3,000 cells/mm3) or for patients of Asian ancestry, positive HLA B\*1502 test.~18. Estimated creatinine clearance \<60 mL/min \[men: (140-age) x weight/serum creatinine x 72; women: (0.85) (140-age) x weight/serum creatinine x 72. Age in years, weight in kg, and serum creatinine in mg/dL\].~19. Pregnant or nursing.~20. Participation in other drug clinical trial within the last 2 months or received an investigational drug within 5 half-lives of this other product, whichever is longer. Patient(s) who are known to have not taken any doses of study drug(s) in earlier study(ies) (e.g. screen-failures) are allowed without any time limitation.~21. Not ensured capability to perform the trial.~22. Any other condition or circumstance that, in the opinion of the Investigator, may compromise the patient's ability to comply with the study protocol.~23. Currently treated with VNS, but implanted \<6 months before screening or parameters not stable for at least 1 month prior to screening.~    At V2 (randomisation), patients must not be/have:~24. Inadequate compliance to concomitant AEDs during the 8-week baseline period or to screening exclusion criteria.~25. Inadequate completion of the study diary.~26. Any other condition or circumstance that, in the opinion of the Investigator, may compromise the patient's ability to comply with the study protocol.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 800 mg QD Eslicarbazepine acetate (Type: ACTIVE_COMPARATOR): tablets
- 1200 mg QD Eslicarbazepine acetate (Type: ACTIVE_COMPARATOR): tablets
- Placebo (Type: PLACEBO_COMPARATOR): tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).